Anibal Chertcoff

EBV & MS risk at ACTRIMS 1:14
EBV & MS risk at ACTRIMS
Anibal Chertcoff • 27 Feb 2023
Phenotyping the prodrome could lead to earlier recognition of MS 3:41
Phenotyping the prodrome could lead to earlier recognition of MS
Anibal Chertcoff • 27 Feb 2023
The burden of psychiatric morbidity in the MS prodrome 4:55
The burden of psychiatric morbidity in the MS prodrome
Anibal Chertcoff • 27 Feb 2023
Future research options in polypharmacy associated with multiple sclerosis 1:45
Future research options in polypharmacy associated with multiple sclerosis
Anibal Chertcoff • 28 Oct 2022
Impacts of polypharmacy on MS patients’ outcomes 2:07
Impacts of polypharmacy on MS patients’ outcomes
Anibal Chertcoff • 28 Oct 2022
Population-based study on polypharmacy and multiple sclerosis 6:12
Population-based study on polypharmacy and multiple sclerosis
Anibal Chertcoff • 28 Oct 2022
Strategies to reduce polypharmacy in multiple sclerosis 2:36
Strategies to reduce polypharmacy in multiple sclerosis
Anibal Chertcoff • 28 Oct 2022
The content of VJNeurology is intended for healthcare professionals